ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio...
The acquisition of ValenzaBio adds multiple clinical and pre-clinical development programs to ACELYRIN’s robust immunology pipeline, which is led by izokibep.
ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy – including in Difficult-to-Treat Manifestations – Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Function
ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases